Core Insights - The total margin balance of the STAR Market reached 155.83 billion yuan on June 25, 2025, marking an increase of 0.36 billion yuan from the previous trading day [1] - This increase has been consistent over three consecutive trading days [1] Financing and Securities Lending Overview - The financing balance amounted to 155.30 billion yuan, with an increase of 0.36 billion yuan compared to the previous day [1] - The securities lending balance was recorded at 0.0527 billion yuan, showing a decrease of 0.00236 billion yuan from the previous trading day [1] Recent Trends in Margin Trading - The margin balance on June 24, 2025, was 155.47 billion yuan, which was an increase of 0.775 billion yuan from June 23 [1] - On June 23, 2025, the margin balance was 154.69 billion yuan, reflecting an increase of 0.165 billion yuan from June 20 [1] - The margin balance on June 20, 2025, was 154.53 billion yuan, which was a decrease of 0.613 billion yuan from June 19 [1]

7月1日，禾元生物科创板IPO申请将上会，其拟采用第五套上市标准引发市场关注。作为科创板第五套上 市标准重启以来首家上会的企业，禾元生物此次被赋予标志性意义，即资本市场对科技创新规律的理解进 一步深化，制度适配性进一步增强。 科创板设立之初，即从科创企业发展的实际出发，允许无收入、未盈利企业通过"市值+研发"指标登陆资 本市场。然而，由于种种原因，自智翔金泰上市后，已两年未有企业采用第五套标准。 如今，科创板有望再次迎来第五套标准上市企业，充分体现了科创板对优质未盈利科技型企业的包容，进 一步彰显了资本市场支持科技创新、服务新质生产力发展的政策导向。 点击关键字可查看 潜望系列深度报道丨 股事会专栏 丨 投资小红书 丨 e公司调查 丨 时报会客厅 丨 十大明星私募访谈 丨 超600%！复牌暴涨！ 丨 重磅！财政部：根据形势变化及时推出增量储备政策 丨 昨夜，中概股大 涨！ 丨 "芯"火"辽"原已成势丨证券时报、辽宁日报联合调研报道 丨 科创板第五套标准重启！禾元生 物IPO即将上会 丨 又有公司进入退市整理期！ 丨 促消费！央行、证监会等联合印发！ 丨 大涨！牛 市旗手，再现百亿成交！ 丨 刚刚，突破！中国资 ...

7月1日，禾元生物科创板IPO申请将上会，其拟采用第五套上市标准引发市场关注。作为科创板第五套 上市标准重启以来首家上会的企业，禾元生物此次被赋予标志性意义，即资本市场对科技创新规律的理 解进一步深化，制度适配性进一步增强。 科创板设立之初，即从科创企业发展的实际出发，允许无收入、未盈利企业通过"市值+研发"指标登陆 资本市场。然而，由于种种原因，自智翔金泰上市后，已两年未有企业采用第五套标准。 如今，科创板有望再次迎来第五套标准上市企业，充分体现了科创板对优质未盈利科技型企业的包容， 进一步彰显了资本市场支持科技创新、服务新质生产力发展的政策导向。 第五套上市标准是科创板制度包容性、适应性的重要体现，是应和科创企业发展规律的重要举措。与传 统企业不同，科技型企业往往具备"研发投入高、盈利周期长、商业验证慢"等成长特性。以新药研发为 例，从实验室成果到商业化落地平均耗时10—15年，需持续投入数十亿元资金，这期间，资本市场的支 持不可或缺。 从美股科技"七巨头"的成长轨迹来看，亚马逊上市后第6年方实现首次盈利，特斯拉更是在上市后第11 年才开始赚钱，苹果、英伟达等龙头企业同样经历了营收大幅下降甚至亏损的阶段。 ...

Core Viewpoint - Beijing Yitang Semiconductor Technology Co., Ltd. is set to conduct an initial public offering (IPO) and list on the Sci-Tech Innovation Board, following the approval from the China Securities Regulatory Commission and the Shanghai Stock Exchange [1][6]. Group 1: IPO Details - The IPO will involve a combination of strategic placement, offline issuance, and online issuance [2][7]. - The stock will be named "Yitang Co., Ltd." with the stock code "688729" for the IPO and "787729" for online subscription [6]. - The initial inquiry period for the IPO is scheduled for June 24, 2025, with a price range of 7.11 to 8.80 yuan per share [7][8]. Group 2: Underwriters - Guotai Junan Securities Co., Ltd. and China International Capital Corporation are the joint lead underwriters for this IPO [2][9]. - The underwriters will manage the strategic placement and the inquiry process for offline and online subscriptions [2]. Group 3: Investor Participation - A total of 247 offline investors submitted 6,203 inquiries, with a total proposed subscription of 38,429,590 shares [7]. - After excluding invalid bids, 6,159 valid bids remained, with a total proposed subscription of 38,214,000 shares [8].

回顾科创板改革历程，完善市场风险管理工具始终是政策重点之一。去年6月19日，证监会发布的《关 于深化科创板改革服务科技创新和新质生产力发展的八条措施》提出，"丰富科创板ETF品类及ETF期权 产品，研究适时推出科创50指数期货期权"。本次《意见》再次强调增加科创板的风险管理工具，意味 着相关衍生品将加速落地。 业内人士认为，衍生品扩容是深化科创板改革、吸引中长期资金的关键举措。通过完善风险管理工具， 更好满足市场多元化需求，能够提升市场稳定性和吸引力，进一步激发科创板的活力与效率。 从科创板现有的金融风险管理工具来看，2023年6月5日，上交所推出科创50ETF期权，成为我国首只基 于科创50指数的场内期权品种，该期权产品包括认购和认沽期权，支持双向交易和"T+0"操作。一德期 货期权分析师曹柏杨告诉期货日报记者，科创50ETF期权上市后，完善了市场风险管理体系，为投资者 提供了非线性对冲工具，降低了科创板高波动性对中长期资金的冲击。 "投资者可通过买入认沽期权对冲市场下跌风险，或利用跨式组合对冲波动性风险，降低持仓波动对收 益的冲击。例如，持有ETF的机构可通过备兑开仓策略（卖出认购期权）增厚收益，同时锁定 ...

Investment Rating - The investment rating for the non-bank financial industry is "Positive" (maintained) [1] Core Viewpoints - The report highlights a significant improvement in market data for the second quarter of 2025, with brokerage firms experiencing a year-on-year increase in trading volume and new account openings [4] - The report anticipates a continued high growth rate for listed brokerage firms' mid-year reports, projecting a year-on-year growth of approximately 50% [4] - The report emphasizes the favorable policies aimed at stabilizing the stock market and boosting the economy, which are expected to benefit the brokerage sector [5] - The report identifies three main investment themes within the brokerage sector: undervalued leading brokers with strong retail business, high beta financial technology stocks, and brokers benefiting from the expansion and activity of the Hong Kong IPO market [6] Summary by Sections Market Data Improvement - In Q2 2025, the average daily stock trading volume reached 12.5 trillion, a year-on-year increase of 48% [4] - The number of new accounts opened from January to May 2025 was 10.95 million, up 30% year-on-year [4] - The margin trading scale as of June 24 was 1.82 trillion, a year-on-year increase of 22% [4] Investment Banking and IPOs - The IPO scale from January to June 2025 was 37.1 billion, with 50 projects, reflecting a year-on-year increase of 14% [4] - The report notes a significant increase in IPO activity in Q2 2025, with a scale of 23.6 billion and 30 projects, representing a quarter-on-quarter increase of 75% [4] Policy Environment - The report discusses the "1+6" policy measures introduced by the China Securities Regulatory Commission, which are expected to facilitate IPOs for unprofitable companies [5] - The report mentions a joint guideline from the central bank and other departments aimed at boosting consumption and stabilizing the economy [5] Valuation and Fund Allocation - The report indicates that public funds are significantly underweight in the non-bank financial sector, with a notable need for reallocation [6] - As of June 25, the brokerage sector's price-to-book (PB) and price-to-earnings (PE) ratios were 1.44 and 20.75, respectively, indicating that valuations remain low [6]

Group 1 - The first company to be reviewed under the restarted fifth set of standards for the Sci-Tech Innovation Board is Wuhan Heyuan Biotechnology Co., Ltd. (Heyuan Bio) [1][3] - Heyuan Bio is an innovative biopharmaceutical company known for its "rice-derived blood" technology and has established a unique plant expression system and two technical platforms [3][4] - The company has adjusted its fundraising target down by approximately 1.1 billion yuan, from an initial 3.502 billion yuan to 2.4 billion yuan, due to steady progress in R&D and business operations [5][6] Group 2 - Heyuan Bio's asset-liability ratio is projected to increase significantly in 2024, with ratios of 18.81%, 23.96%, and 43.37% for the years 2022 to 2024 respectively [6][7] - The company has not yet achieved profitability, with reported revenues of approximately 13.4 million yuan, 24.3 million yuan, and 25.2 million yuan for the years 2022 to 2024, and net losses of approximately 144 million yuan, 187 million yuan, and 151 million yuan for the same period [7] - Heyuan Bio's core product, HY1001, is expected to be approved for market launch soon, having completed its Phase III clinical trials with promising results [7][8] Group 3 - The recent policy changes by the China Securities Regulatory Commission aim to enhance the inclusivity and adaptability of the Sci-Tech Innovation Board, facilitating the listing of unprofitable companies [4] - Other companies currently in the review process under the fifth set of standards include Beixin Life, Hengrun Da, Sizherui, and Bibete, with some making faster progress than others [8][9]

因为 A 股市场为了保护股民利益收紧，这两年来港交所这次捡了不少漏，尤其对现金流较差早期融资节奏太 快的企业，因为资金链和盈利性问题，只能选择跑到港股上市，这使得 A 股错失不少机器人企业。 为了抢救市场， 6 月 18 日，在 2025 陆家嘴论坛上证监会主席 吴清 表示，创业板正式启用第三套标准， 支持优质未盈利创新企业上市。将继续充分发挥科创板示范效应，加力推出进一步深化改革的 1+6 政策措 施，重启未盈利企业适用科创板第五套标准 ( 允许符合国家战略、突破关键核心技术且市场认可度高的企 业，在无盈利情况下以预计市值 40 亿元门槛上市 ) 上市 。 证监会表示在持续抓好 " 科创板八条 " 落地实施的基础上，以设置专门层次为抓手，重启未盈利企业适用科 创板第五套标准上市，推出一揽子更具包容性、适应性的制度改革，着力打通支持优质科技型企业发展的堵点 难点，同时进一步加强投资者合法权益保护。一方面，设置科创板科创成长层，在科创成长层的定位、企业入 层和调出条件、强化信息披露和风险揭示、增加投资者适当性管理等方面明确具体要求。另一方面，围绕增强 优质科技型企业的制度包容性适应性，推出 6 项改革举措。 值 ...

Group 1 - The core point of the news is that the main funds in the Shanghai and Shenzhen markets experienced a net inflow of 7.138 billion yuan, with the Sci-Tech Innovation Board seeing a net outflow of 323 million yuan [1] - A total of 233 stocks saw net inflows, while 355 stocks experienced net outflows [1] - On the Sci-Tech Innovation Board, 452 stocks rose, with one stock, Tai Lingwei, hitting the daily limit, while 126 stocks declined [1] Group 2 - The top three stocks with the highest net inflow of main funds are: Han's Laser with 362 million yuan, SMIC with 349 million yuan, and Tai Lingwei with 107 million yuan [2] - The stock with the highest net outflow was Guangda Special Materials, which saw a net outflow of 158 million yuan despite a price increase of 2.91% [1][2] - There are 62 stocks that have seen continuous net inflows for more than three trading days, with Sanyou Medical leading at 10 consecutive days [2] Group 3 - The main funds' inflow ranking shows that Han's Laser had an inflow rate of 6.40% and a price increase of 0.64% [2] - Other notable stocks include Kingsoft Office with an inflow of 101 million yuan and a price increase of 3.87%, and Wealth Trend with an inflow of 100 million yuan and a price increase of 17.84% [2] - A total of 114 stocks experienced continuous net outflows, with Bohui Technology leading at 24 consecutive days of outflow [2]

今日A股集体飘红，科创50指数ETF（588870）午后走高，盘中大涨1.59%冲击三连阳，换手率已近15%！资金积极布局，科创50指数ETF(588870) 近60日净流入超1.3亿元，年内份额增长率超25%，持续领先同类！ 科创50指数ETF(588870)标的指数成分股多数上涨：中午人机涨超5%，中芯国际、金山办公涨超2%，澜起科技、恒玄科技、佰维存储涨超1%，海 光信息、中微公司微涨。 【机构点评：本轮科创板改革或带来哪些影响？】 消息面上，6月18日，《关于在科创板设置科创成长层，增强制度包容性适应性的意见》发布，重启科创板第五套上市标准，将适用范围从生物医 药扩展至人工智能、商业航天、低空经济等前沿科技领域企业。华泰证券认为，科创板第五套上市标准核心指标为：1）预计市值不低于40亿元； 2）研发成果：主业或产品需经国家有关部门批准，市场空间大，目前已取得阶段性成果。 华泰证券表示，本次科创板制度改革为高层对新兴产业资本运作的实质性支持，有望拓宽行业领军企业融资渠道。建议关注政策红利下商业航天、 低空经济产业发展机遇。商业航天及低空经济支持政策日渐完善，商业化落地加速，产业处于规模化发展前期。看好产 ...